Vincristine Interactions

Increased exposure of chemotherapeutic agent may increase risk of adverse reactions. Monitor for chemotherapeutic-related adverse reactions.

Source: NLP:fosaprepitant dimeglumine

Associated with myelosuppression or nephrotoxicity; coadministration should be considered only if potential benefits outweigh risks.

Source: NLP:ganciclovir sodium

Co-administration with valganciclovir should be considered only if potential benefits outweigh risks due to potential for higher toxicity from myelosuppression or nephrotoxicity.

Source: NLP:valganciclovir hydrochloride

Increased exposure of chemotherapeutic agent may increase risk of adverse reactions. Monitor for chemotherapeutic-related adverse reactions.

Source: NLP:aprepitant

Increased exposure of chemotherapeutic agent may increase risk of adverse reactions. Monitor for chemotherapeutic-related adverse effects.

Source: NLP:fosaprepitant

MultiHance may compete for MOAT transporter and prolong systemic exposure of vincristine.

Source: NLP:gadobenate dimeglumine

Associated with myelosuppression or nephrotoxicity. Coadministration considered only if benefits outweigh risks.

Source: NLP:ganciclovir

Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.

Source: NLP:netupitant and palonosetron

Drug associated with myelosuppression or nephrotoxicity. Consider coadministration only if potential benefits outweigh risks.

Source: NLP:valganciclovir

Suspected of causing SIADH; may increase pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended.

Source: NLP:vasopressin

May cause SIADH, increasing pressor and antidiuretic effects of vasopressin. Hemodynamic monitoring recommended; adjust vasopressin dose as needed.

Source: NLP:vasopressin in 0.9% sodium chloride